Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Intellia Thera CS (NTLA)
Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,744,861
  • Shares Outstanding, K 89,555
  • Annual Sales, $ 52,120 K
  • Annual Income, $ -474,190 K
  • 60-Month Beta 1.76
  • Price/Sales 53.32
  • Price/Cash Flow N/A
  • Price/Book 2.58
Trade NTLA with:

Options Overview Details

View History
  • Implied Volatility 70.41% ( +1.24%)
  • Historical Volatility 85.24%
  • IV Percentile 71%
  • IV Rank 64.90%
  • IV High 84.12% on 02/21/23
  • IV Low 45.07% on 09/20/23
  • Put/Call Vol Ratio 0.30
  • Today's Volume 397
  • Volume Avg (30-Day) 1,510
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 29,221
  • Open Int (30-Day) 22,384

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.51
  • Number of Estimates 12
  • High Estimate -1.33
  • Low Estimate -1.66
  • Prior Year -1.40
  • Growth Rate Est. (year over year) -7.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.67 +37.00%
on 11/13/23
31.90 -2.66%
on 11/24/23
+7.89 (+34.07%)
since 10/27/23
3-Month
22.67 +37.00%
on 11/13/23
38.72 -19.81%
on 08/29/23
-6.96 (-18.31%)
since 08/28/23
52-Week
22.67 +37.00%
on 11/13/23
51.94 -40.22%
on 11/30/22
-17.21 (-35.66%)
since 11/28/22

Most Recent Stories

More News
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market

These stocks may take off in a market favoring growth.

CRSP : 70.78 (-1.16%)
TDOC : 17.86 (+3.78%)
NTLA : 31.12 (+1.53%)
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years

Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.

PFE : 29.68 (-1.53%)
REGN : 800.35 (+0.28%)
NTLA : 31.12 (+1.53%)
Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?

There's more to being a good investment than doing groundbreaking science.

PFE : 29.68 (-1.53%)
NTLA : 31.12 (+1.53%)
3 Stocks Cathie Wood Is Buying That Should Be on Your List Too

The three companies are positioned to benefit from red-hot trends.

NTLA : 31.12 (+1.53%)
SQ : 63.59 (+5.44%)
DNA : 1.4150 (+1.80%)
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time

Wood is going all in on gene editing.

CRSP : 70.78 (-1.16%)
NTLA : 31.12 (+1.53%)
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying

These two large-cap biopharma companies could have more room to run.

SNY : 47.03 (-1.30%)
NTLA : 31.12 (+1.53%)
REGN : 800.35 (+0.28%)
VRTX : 346.90 (-0.94%)
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years

These two gene-editing stocks could be diamonds in the rough.

AAPL : 189.81 (+0.01%)
TSLA : 245.46 (+3.97%)
LLY : 591.51 (unch)
BRK.A : 547,700.00 (+0.05%)
BRK.B : 361.12 (-0.06%)
CRSP : 70.78 (-1.16%)
NTLA : 31.12 (+1.53%)
2 Brilliant Growth Stocks to Buy and Hold Forever

These two growth stocks could be genuine wealth escalators.

NTLA : 31.12 (+1.53%)
PLTR : 19.67 (+3.09%)
Down 45%, Is Intellia a Buy?

Intellia's operating in the high-growth field of gene editing.

REGN : 800.35 (+0.28%)
NTLA : 31.12 (+1.53%)
This Cathie Wood Stock Is Poised to Double, Says Wall Street

Almost anything is possible in the volatile biotech industry.

NTLA : 31.12 (+1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 33.02
2nd Resistance Point 32.09
1st Resistance Point 31.37
Last Price 31.12
1st Support Level 29.72
2nd Support Level 28.79
3rd Support Level 28.07

See More

52-Week High 51.94
Fibonacci 61.8% 40.76
Fibonacci 50% 37.30
Fibonacci 38.2% 33.85
Last Price 31.12
52-Week Low 22.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar